Skip to main content
Premium Trial:

Request an Annual Quote

Courtagen Acquires Medicinal Genomics

NEW YORK (GenomeWeb News) – Courtagen Life Sciences today said that it has acquired Medicinal Genomics, a Marblehead, Mass.-based firm that has sequenced the genome of Cannabis sativa and Cannabis indica.

Medicinal Genomics has been researching the genomics and medical use of cannabis. The firm's founder and CEO, Kevin McKernan, has joined Courtagen as chief scientific officer. Woburn, Mass.-based Courtagen is headed by his two brothers, CEO Brian McKernan and President Brendan McKernan. The three brothers were founders of Agencourt Bioscience, which was sold to Beckman Coulter in 2005, and Agencourt Personal Genomics, which was sold to Applied Biosystems the following year.

Financial terms of the acquisition were not disclosed.

"We believe that Kevin's groundbreaking work at Medicinal Genomics is completely aligned with Courtagen's objective of turning sophisticated genomics into tools that will provide real clinical utility," Brian McKernan said in a statement.

Last summer, Medicinal Genomics said that it had sequenced the genomes of two cannabis strains using Roche 454 Life Sciences' platform.

Medicinal Genomics will operate as a wholly owned subsidiary of Courtagen and will continue to apply next-generation sequencing technologies to better understand and elucidate the medical properties of Cannabis.

For more on Courtagen's plans for the clinical sequencing market, see GenomeWeb Daily News sister publication.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.